STOCKS TELEGRAPH

Tag: HTGM

  • HTC Molecular Diagnostics Inc. (HTGM) Soar on Proprietary Technology Features Expansion

    HTC Molecular Diagnostics Inc. (HTGM) Soar on Proprietary Technology Features Expansion

    After the market closed on April 6, 2022, HTC Molecular Diagnostics Inc. (HTGM) announced new features of its proprietary HTG EdgeSeq technology. The news caused a rally in the stock as it soared by a huge 39.06%. Thus, HTGM was trending at a price of $1.78 per share in the after-hours while a heavy volume of 2.51 million shares was exchanged.

    Source: BioSpectrum

    It seems rebound energy had also a role to play as the recovery came after the stock plunged to a new low of $1.25 in the prior session.

    HTGM’s Latest Developments

    The company has improved its proprietary technology such that new sample preparations harmonization now enables miRNA and mRNA profiling without needing additional samples. The improved sample preparation protocol for its miRNA WTA (Whole Transcriptome Assay) is thus harmonized with HTP (HTG Transcriptome Panel). Therefore, using a single sample lysate, customers can process a sample with HTGM’s transcriptome panels of 20,000 gene mRNA and 20,000+ miRNA.

    Previously, full transcriptome analysis required separate tissue sections and sample preparation processes. With the completion of this harmonization, a single tissue section and one lysis method are expected to be required.

    In simple terms, the new development will allow streamlined workflow with crucial samples retention for use in other analyses.

    Molecular Diagnostic’s Role and Future

    Molecular diagnostics are used in the analysis of biomarkers for multiple ailments including contagious diseases, cancer, and chronic diseases among others. Technological advancement in the field has brought about a huge upsurge in R&D efforts in the healthcare industry. Furthermore, the outbreak of infectious diseases particularly covid-19 has also been a driver in fueled innovations and developments in the field. All the subsets of the field ranging from oncology molecular diagnostics to veterinary molecular diagnostics are deemed to grow substantially in the future. The overall molecular diagnostics market is expected to grow at a CAGR of 10.90% to USD 32.10 billion by 2027.

    HTGM’s Outlook

    The company’s recently commercialized HTP assay marked a nice chunk of 16% of its 2021 revenue just 5 months after the launch. With the strengthening of its team and the release of its first white paper featuring drug discovery through its proprietary platform on top of the latest development, HTGM is progressing well into 2022.

    Conclusion

    Increased efficiency, reduced turnaround times, simplified bioinformatics, and sample retention are some of the added benefits of HTGM’s latest development. Hence, the news of this latest feature expansion of its proprietary technology caused the stock to rally big in the after-hours on Wednesday.

  • 10 Of The Best Diagnostics Research Industry Stocks To Buy For 2020

    10 Of The Best Diagnostics Research Industry Stocks To Buy For 2020

    Healthcare is a dynamic and opportunity-rich industry. The demand for innovations that brings improvement in health outcomes, affordability, quality, and access will continue to be high. The changes we witnessed in the healthcare industry today have set a new tone for the change in the coming few years. 2020 is the year of change for the health care industry.

    The first thing which played an important role in the healthcare industry is Technology. Technology is continuously changing and brings new improvement in the healthcare industry. Patients today want easier and affordable access to care and better demand services. In this changing environment, diagnostics is emerging as a key driver in helping to address these needs.

    Here are the top 10 leading companies in Diagnostics Research Industry that need your attention:

    OPKO Health Inc. (NASDAQ: OPK)

    OPKO Health Inc. (NASDAQ: OPK) shares were trading down -0.92% at $3.22 at the time of writing on Tuesday. OPKO Health Inc. (NASDAQ: OPK) share price went from a low point around $1.12 to briefly over $6.47 in the past 52 weeks, though shares have since pulled back to $3.22. OPK market cap has remained high, hitting $2.13B at the time of writing, giving it a price-to-sales ratio of more than 2.

    OPKO Health Inc. has earlier started a Phase 2 trial with RAYALDEE as a treatment for mild-to-moderate COVID-19.  If we look at the recent analyst rating OPK, Piper Jaffray initiated coverage on OPK shares with an Overweight rating.

    Pacific Biosciences of California Inc. (NASDAQ: PACB)

    Pacific Biosciences of California Inc. (NASDAQ: PACB) last closed at $8.78, in a 52-week range of $2.20 to $8.38. Analysts have a consensus price target of $6.50. Pacific Biosciences of California Inc. (PACB) has announced it has appointed Susan G. Kim as Chief Financial Officer. The decision is effective as of September 28, 2020. Susan has joined the company at a time when there are various growth opportunities for the company.

    Bionano Genomics Inc. (NASDAQ: BNGO)

    Bionano Genomics Inc. (NASDAQ: BNGO) stock soar by 0.79% to $0.64. The most recent rating by Oppenheimer, on April 08, 2020, is at an Outperform. Bionano Genomics Inc. (BNGO) will participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. the summit is scheduled to take place virtually on September 21-23, 2020. This company market capitalization has remained high, hitting $90.45 million at the time of writing.

    Illumina Inc. (NASDAQ: ILMN)

    Illumina Inc. (NASDAQ: ILMN) shares headed falling, lower as much as -0.60%. The most recent rating by UBS, on September 22, 2020, is at a Neutral. Illumina Inc. (ILMN) has officially revealed an agreement to buy cancer-testing company Grail for about $8 billion in cash and stock. This company market capitalization has remained high, hitting $39.54 billion at the time of writing.

    Precipio Inc. (NASDAQ: PRPO)

    Precipio Inc. (NASDAQ: PRPO) shares headed rising, higher as much as 2.63%. Precipio Inc. has revealed that it has introduced its HemeScreen AML (Acute Myeloid Leukemia) panel both clinically in its CLIA laboratory, and as part of its HemeScreen product offering. This company market capitalization has remained high, hitting 37.42 million at the time of writing.

    Fulgent Genetics Inc. (NASDAQ: FLGT)

    Fulgent Genetics Inc. (NASDAQ: FLGT) stock soar by 7.08% to $40.25. The most recent rating by Oppenheimer, on August 20, 2020, is at an Outperform. Fulgent Genetics Inc. (FLGT) will replace Garrett Motion Inc. (GTX) in the S&P SmallCap 600 effective before the opening of trading on Friday, September 25. This company’s market capitalization has remained high, hitting $821.10 million at the time of writing.

    Fluidigm Corporation (NASDAQ: FLDM)

    Fluidigm Corporation (NASDAQ: FLDM) fall -1.29% after losing more than -$0.11 on Tuesday. In the past 52-weeks of trading, this company’s stock fluctuated between the low range of $1.17 and a high range of $12.45. It has moved up 595.73% from its 52-weeks low and moved down -34.62% from its 52-weeks high. Looking at its liquidity it has a current ratio of 2.00. This company’s market capitalization has remained high, hitting $523.91 million at the time of writing.

    Invitae Corporation (NYSE: NVTA)

    Invitae Corporation (NYSE: NVTA) last closed at $43.10, in a 52-week range of $7.41 to $40.96. Analysts have a consensus price target of $36.25. Invitae Corporation (NVTA) has moved up 475.19% from its 52-weeks low and moved down -2.16% from its 52-weeks high. Looking at its liquidity it has a current ratio of 3.70. This company’s market capitalization has remained high, hitting $5.56 billion at the time of writing.

    HTG Molecular Diagnostics Inc. (NASDAQ: HTGM)

    HTG Molecular Diagnostics Inc. (NASDAQ: HTGM) fall -8.01% after losing more than -$0.03 on Tuesday. HTG Molecular Diagnostics Inc. (HTGM) share price went from a low point around $0.27 to briefly over $0.99 in the past 52 weeks, though shares have since pulled back to $0.32. HTG Molecular Diagnostics Inc. market cap has remained high, hitting $22.70 million at the time of writing

    Co-Diagnostics Inc. (NASDAQ: CODX)

    Co-Diagnostics Inc. (NASDAQ: CODX) last closed at $14.93, in a 52-week range of $0.85 to $30.99. Co-Diagnostics Inc. (CODX) has moved up 1567.08% from its 52-weeks low and moved down -54.47% from its 52-weeks high. Looking at its liquidity it has a current ratio of 11.60. This company’s market capitalization has remained high, hitting $404.90 million at the time of writing.